It is generally thought that FGF21 could be a potential therapeutic agent for metabolic diseases, such as diabetes (including NASH), and synthetic recombinant human FGF21 (rhFGF21) has now entered clinical trials. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatohepatitis.